G. Larson

发表

Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors.

Gary Larson, Shunqi Yan, J. Wu, 2006, Bioorganic & medicinal chemistry letters.

Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure.

Gary Larson, Shunqi Yan, J. Wu, 2007, Bioorganic & medicinal chemistry letters.

Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors.

Gary Larson, Shunqi Yan, J. Wu, 2007, Bioorganic & medicinal chemistry letters.

Dual-Action Mechanism of Viramidine Functioning as a Prodrug and as a Catabolic Inhibitor for Ribavirin

J. Wu, Z. Hong, G. Larson, 2004, Antimicrobial Agents and Chemotherapy.

Interaction of the antitumor compound cryptophycin-52 with tubulin.

G. Larson, D. Panda, M. Jordan, 2000, Biochemistry.

2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules

G. Larson, D. Panda, M. Jordan, 2006, Molecular Cancer Therapeutics.

Structure of human uridine-cytidine kinase 2 determined by SIRAS using a rotating-anode X-ray generator and a single samarium derivative.

I. W. Cheney, J. Wu, Z. Hong, 2005, Acta crystallographica. Section D, Biological crystallography.

Parallel synthesis of pteridine derivatives as potent inhibitors for hepatitis C virus NS5B RNA-dependent RNA polymerase.

J. Wu, W. Zhong, G. Larson, 2005, Bioorganic & medicinal chemistry letters.

Parallel synthesis of 5-cyano-6-aryl-2-thiouracil derivatives as inhibitors for hepatitis C viral NS5B RNA-dependent RNA polymerase.

J. Wu, N. Yao, G. Larson, 2006, Bioorganic chemistry.

Phosphorylation of Ribavirin and Viramidine by Adenosine Kinase and Cytosolic 5′-Nucleotidase II: Implications for Ribavirin Metabolism in Erythrocytes

J. Wu, Z. Hong, G. Larson, 2005, Antimicrobial Agents and Chemotherapy.

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.

R. Hamatake, A. Maderna, T. Appleby, 2009, Cancer research.

Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2

J. Wu, Z. Hong, D. Delia, 2007, Molecular Cancer Therapeutics.

Identification of novel, selective and potent Chk2 inhibitors.

Shunqi Yan, Huanming Chen, J. Wu, 2007, Bioorganic & medicinal chemistry letters.

RDEA119: A potent and highly selective MEK inhibitor for the treatment of cancer

Shunqi Yan, R. Hamatake, G. Larson, 2007 .

Enzymatic removal from various tissues of the galactose alpha 1,3-galactose target antigens of human antispecies antibodies.

K. Welsh, G. Larson, T. Cairns, 1994, Transplantation Proceedings.

Selection of 3′-Template Bases and Initiating Nucleotides by Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase

Z. Hong, G. Larson, J. Shim, 2002, Journal of Virology.